Design and synthesis of 1-indol-1-yl-propan-2-ones as inhibitors of human cytosolic phospholipase A2α

被引：70

作者：

Ludwig, J ^{[1
]}

Bovens, S ^{[1
]}

Brauch, C ^{[1
]}

Elfringhoff, AS ^{[1
]}

Lehr, M ^{[1
]}

机构：

[1] Univ Munster, Inst Pharmaceut & Med Chem, D-48149 Munster, Germany

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2006年 / 49卷 / 08期

关键词：

D O I：

10.1021/jm051243a

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The synthesis and structure-activity relationship study of a series of 1-indol-1-yl-3-phenoxypropan-2-one inhibitors of cytosolic phospholipase A(2)alpha (cPLA(2)alpha) are described. The compounds were evaluated in a vesicle assay with isolated cPLA(2)alpha and in cellular assays with intact human platelets. Systematic variation led to 3-methylhydrogen 1-[3-(4-decyloxyphenoxy)-2-oxopropyl]indole-3,5-dicarboxylate (57), which revealed the highest activity against the isolated enzyme. With an IC50 value of 4.3 nM in this assay, it is one of the most potent in vitro cPLA(2)alpha inhibitors known today.

引用

页码：2611 / 2620

页数：10

共 36 条

[1] Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A(2) [J].

Bonventre, JV ;

Huang, ZH ;

Taheri, MR ;

OLeary, E ;

Li, E ;

Moskowitz, MA ;

Sapirstein, A .

NATURE, 1997, 390 (6660) :622-625

[2] Cytosolic phospholipase A2α reigns supreme in arthritis and bone resorption [J].

Bonventre, JV .

TRENDS IN IMMUNOLOGY, 2004, 25 (03) :116-119

[3] Potential therapeutic uses of phospholipase A2 inhibitors [J].

Clark, JD ;

Tam, S .

EXPERT OPINION ON THERAPEUTIC PATENTS, 2004, 14 (07) :937-950

[4] Design and synthesis of a novel and potent series of inhibitors of cytosolic phospholipase A2 based on a 1,3-disubstituted propan-2-one skeleton [J].

Connolly, S ;

Bennion, C ;

Botterell, S ;

Croshaw, PJ ;

Hallam, C ;

Hardy, K ;

Hartopp, P ;

Jackson, CG ;

King, SJ ;

Lawrence, L ;

Mete, A ;

Murray, D ;

Robinson, DH ;

Smith, GM ;

Stein, L ;

Walters, I ;

Wells, E ;

Withnall, WJ .

JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (06) :1348-1362

[5]

Connolly S., 1995, EXPERT OPIN THER PAT, V5, P673, DOI DOI 10.1517/13543776.5.7.673

[6]

CONNOLLY S, 2002, ABSTRACT BOOK

[7]

CONNOLLY S, 1993, EXPERT OPIN THER PAT, V3, P1141

[8]

FABIAN J, 2005, ANN M GERM PHARM SOC

[9] Structure-activity relationship studies of 3-dodecanoylindole-2-carboxylic acid inhibitors of cytosolic phospholipase A2α-mediated arachidonic acid release in intact platelets:: variation of the keto moiety [J].

Ghasemi, A ;

Elfringhoff, AS ;

Lehr, M .

JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2005, 20 (05) :429-437

[10] Trifluoromethyl ketones and methyl fluorophosphonates as inhibitors of group IV and VI phospholipases A2:: structure-function studies with vesicle, micelle, and membrane assays [J].

Ghomashchi, F ;

Loo, R ;

Balsinde, J ;

Bartoli, F ;

Apitz-Castro, R ;

Clark, JD ;

Dennis, EA ;

Gelb, MH .

BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1999, 1420 (1-2) :45-56

← 1 2 3 4 →